Latest Breaking News On - Oncologic drugs advisory committee - Page 1 : comparemela.com

Whither CAR T? Will the FDA Being Under the Hood and the Availability of Bispecifics Make These Therapies Less Attractive?

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia platforms.

Fox-chase-cancer-center
Pennsylvania
United-states
Virginia
Philadelphia
Andrew-hertler
Garrick-wong
Amy-vangalder
Justin-tse
Seimetzd-catumaxomab
Oncologic-drugs-advisory-committee
National-cancer-institute

Health Care Week In Review: House Held Oversight Hearing on the 340B Program and HHS Expanded Certified Community Behavioral Health Clinics | Alston & Bird

Health Care Week In Review: House Held Oversight Hearing on the 340B Program and HHS Expanded Certified Community Behavioral Health Clinics | Alston & Bird
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.

Iowa
United-states
Indiana
New-mexico
Tennessee
Louisiana
Rhode-island
Kansas
California
New-hampshire
Kentucky
Maine

Dr Landgren on the Rationale for Utilizing MRD as a Clinical Trial End Point in Myeloma

Ola Landgren, MD, PhD, discusses the background for utilizing MRD as a clinical trial end point when evaluating multiple myeloma treatment.

Miami
Florida
United-states
University-of-miami
Paulj-dimare
C-ola-landgren
National-cancer-institute
Clinical-oncology-program
Oncologic-drugs-advisory-committee
Sylvester-myeloma-institute
University-of-miami-health-system

Dr Baljevic on the PERSEUS Trial in Untreated Multiple Myeloma

Muhamed Baljevic, MD, FACP, discusses the phase 3 PERSEUS trial in patients with previously untreated multiple myeloma.

United-states
America
Muhamed-baljevic
Vanderbilt-amyloidosis-multidisciplinary-program
Division-of-hematology-oncology
Vanderbilt-ingram-cancer-center
Oncologic-drugs-advisory-committee
Vanderbilt-ingram-cancer-center-protocol
Plasma-cell-disorders-research
Hematology-oncology
Vanderbilt-ingram-cancer-center-protocol-review
Monitoring-system

First-Line Quadruplet Regimens Continue to Enhance Outcomes in Myeloma

Muhamed Baljevic, MD, FACP, discusses the evolution of quadruplet combination therapies in frontline multiple myeloma.

Tennessee
United-states
Nashville
American
Muhamed-baljevic
Plasma-cell-disorders-research
Division-of-hematology-oncology
Vanderbilt-ingram-cancer-center-protocol
Oncologic-drugs-advisory-committee
Vanderbilt-stem-cell-transplant
Cellular-therapy
Vanderbilt-amyloidosis-multidisciplinary-program